GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on March 31, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any significant new risks.
Key Players & Entities
- GSK plc (company) — Filer of the report
- Citigroup Global Markets Limited (company) — Corporate stockbroker for the share purchase
- March 2025 (date) — Reporting period for the transaction
- 31 March 2025 (date) — Date of the announcement and transaction
FAQ
What was the specific number of GSK ordinary shares purchased?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What was the total dollar amount of the share repurchase program?
The filing does not disclose the total dollar amount spent on the share repurchase.
On what exact date did the share purchase occur?
The filing indicates the purchase occurred on 31 March 2025.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK's corporate stockbroker.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding GSK plc (GLAXF).